Trial Profile
Phase I study of ZD6474 [vandetanib] and temozolomide in patients with advanced cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Vandetanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 19 Feb 2008 New trial record.